Atrasentan ( DrugBank: Atrasentan )
3 diseases
| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 66 | IgA腎症 | 7 |
| 218 | アルポート症候群 | 1 |
| 222 | 一次性ネフローゼ症候群 | 3 |
66. IgA腎症
臨床試験数 : 255 / 薬物数 : 255 - (DrugBank : 79) / 標的遺伝子数 : 35 - 標的パスウェイ数 : 137
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2020-003084-26-CZ (EUCTR) | 24/11/2021 | 13/07/2021 | A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Atrasentan in Patients with IgA Nephropathy at Risk of Progressive Loss of Renal Function (The ALIGN Study) | A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Atrasentan in Patients with IgA Nephropathy at Risk of Progressive Loss of Renal Function (The ALIGN Study) - the ALIGN Study | Immunoglobulin A Nephropathy (IgAN);Therapeutic area: Diseases [C] - Immune System Diseases [C20] | Product Name: atrasentan INN or Proposed INN: atrasentan Other descriptive name: ATRASENTAN | Chinook Therapeutics U.S., Inc. | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 320 | Phase 3 | United States;Portugal;Czechia;Taiwan;Hong Kong;Spain;Ireland;Colombia;United Kingdom;Italy;India;France;Czech Republic;Canada;Argentina;Poland;Brazil;Australia;Germany;New Zealand;Japan;China;Korea, Republic of | ||
| 2 | EUCTR2020-003084-26-PL (EUCTR) | 13/07/2021 | 28/01/2021 | A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Atrasentan in Patients with IgA Nephropathy at Risk of Progressive Loss of Renal Function (The ALIGN Study) | A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Atrasentan in Patients with IgA Nephropathy at Risk of Progressive Loss of Renal Function (The ALIGN Study) - the ALIGN Study | Immunoglobulin A Nephropathy (IgAN);Therapeutic area: Diseases [C] - Immune System Diseases [C20] | Product Name: atrasentan INN or Proposed INN: atrasentan Other descriptive name: ATRASENTAN | Chinook Therapeutics U.S., Inc. | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 320 | Phase 3 | United States;Portugal;Czechia;Taiwan;Hong Kong;Spain;Ireland;Colombia;United Kingdom;Italy;India;France;Canada;Argentina;Poland;Brazil;Australia;Germany;New Zealand;Japan;China;Korea, Republic of | ||
| 3 | EUCTR2020-003084-26-IT (EUCTR) | 08/06/2021 | 08/06/2021 | A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Atrasentan in Patients with IgA Nephropathy at Risk of Progressive Loss of Renal Function (The ALIGN Study) | A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Atrasentan in Patients with IgA Nephropathy at Risk of Progressive Loss of Renal Function (The ALIGN Study) - ALIGN | Immunoglobulin A Nephropathy (IgAN);Therapeutic area: Diseases [C] - Immune System Diseases [C20] | Product Name: Atrasentan Product Code: [Atrasentan] INN or Proposed INN: Atrasentan | CHINOOK THERAPEUTICS, U.S., Inc | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 320 | Phase 3 | United States;Hong Kong;Taiwan;Spain;United Kingdom;Italy;India;France;Canada;Argentina;Poland;Brazil;Australia;Germany;China;Japan;New Zealand;Korea, Republic of | ||
| 4 | JPRN-jRCT2071210028 | 01/06/2021 | 25/05/2021 | The ALIGN Study is a phase 3, double-blind, placebo-controlled study to compare the efficacy and safety of atrasentan to placebo in patients with IgA nephropathy (IgAN) at risk of progressive loss of renal function | A Phase 3, Randomized, Double-blind, Placebocontrolled Study of Atrasentan in Patients with IgA Nephropathy at Risk of Progressive Loss of Renal Function - The ALIGN Study | IgA Nephropathy at Risk of Progressive Loss of Renal Function | Drug: Atrasentan Film-coated tablet Other Names: CHK-01 Atrasentan Hydrochloride ABT-627 Drug: Placebo Film-coated tablet | Yamada Shuji | NULL | Pending | >= 18age old | Not applicable | Both | 24 | Phase 3 | Argentina;Australia;Brazil;Canada;China;Colombia;Czech Republic;France;Germany;Hong Kong;India;Italy;New Zealand;Poland;South Korea;Spain;Taiwan;United Kingdom;United States;Japan |
| 5 | EUCTR2020-003084-26-DE (EUCTR) | 08/04/2021 | 21/12/2020 | A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Atrasentan in Patients with IgA Nephropathy at Risk of Progressive Loss of Renal Function (The ALIGN Study) | A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Atrasentan in Patients with IgA Nephropathy at Risk of Progressive Loss of Renal Function (The ALIGN Study) - the ALIGN Study | Immunoglobulin A Nephropathy (IgAN);Therapeutic area: Diseases [C] - Immune System Diseases [C20] | Product Name: atrasentan INN or Proposed INN: atrasentan Other descriptive name: ATRASENTAN | Chinook Therapeutics U.S., Inc. | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 320 | Phase 3 | United States;Hong Kong;Taiwan;Spain;United Kingdom;Italy;India;France;Argentina;Poland;Brazil;Australia;Germany;China;Japan;New Zealand;Korea, Republic of | ||
| 6 | NCT04573920 (ClinicalTrials.gov) | February 1, 2021 | 28/9/2020 | Atrasentan in Patients With Proteinuric Glomerular Diseases | A Phase 2, Open-Label, Basket Study of Atrasentan in Patients With Proteinuric Glomerular Diseases | IgA Nephropathy;Focal Segmental Glomerulosclerosis;Alport Syndrome;Diabetic Kidney Disease;Diabetic Nephropathy Type 2;Immunoglobulin A Nephropathy | Drug: Atrasentan | Chinook Therapeutics U.S., Inc. | NULL | Recruiting | 18 Years | N/A | All | 80 | Phase 2 | United States;Australia;Italy;Korea, Republic of;Spain;United Kingdom |
| 7 | NCT04573478 (ClinicalTrials.gov) | December 11, 2020 | 12/9/2020 | Atrasentan in Patients With IgA Nephropathy | A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Atrasentan in Patients With IgA Nephropathy at Risk of Progressive Loss of Renal Function | IgA Nephropathy;Immunoglobulin A Nephropathy | Drug: Atrasentan;Drug: Placebo | Chinook Therapeutics U.S., Inc. | NULL | Recruiting | 18 Years | N/A | All | 320 | Phase 3 | United States;Australia;Brazil;Canada;France;Germany;Hong Kong;Italy;Japan;Korea, Republic of;New Zealand;Poland;Spain;Taiwan |
218. アルポート症候群
臨床試験数 : 26 / 薬物数 : 33 - (DrugBank : 13) / 標的遺伝子数 : 6 - 標的パスウェイ数 : 29
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04573920 (ClinicalTrials.gov) | February 1, 2021 | 28/9/2020 | Atrasentan in Patients With Proteinuric Glomerular Diseases | A Phase 2, Open-Label, Basket Study of Atrasentan in Patients With Proteinuric Glomerular Diseases | IgA Nephropathy;Focal Segmental Glomerulosclerosis;Alport Syndrome;Diabetic Kidney Disease;Diabetic Nephropathy Type 2;Immunoglobulin A Nephropathy | Drug: Atrasentan | Chinook Therapeutics U.S., Inc. | NULL | Recruiting | 18 Years | N/A | All | 80 | Phase 2 | United States;Australia;Italy;Korea, Republic of;Spain;United Kingdom |
222. 一次性ネフローゼ症候群
臨床試験数 : 285 / 薬物数 : 285 - (DrugBank : 108) / 標的遺伝子数 : 62 - 標的パスウェイ数 : 191
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2020-004176-18-ES (EUCTR) | 21/06/2021 | 09/02/2021 | A Phase 2, Open-Label, Basket Study of Atrasentan in Patients with Proteinuric Glomerular Diseases (The AFFINITY Study) | A Phase 2, Open-Label, Basket Study of Atrasentan in Patients with Proteinuric Glomerular Diseases (The AFFINITY Study) - The AFFINITY Study | Proteinuric glomerular diseases, including:Immunoglobulin A nephropathy (IgAN) (with UPCR 0.5 to <1.0 g/g)Focal segmental glomerulosclerosis (FSGS)Alport SyndromeDiabetes kidney disease (DKD) (as add-on to RAS and sodium glucose co-transporter 2 [SGLT2] inhibitors);Therapeutic area: Diseases [C] - Immune System Diseases [C20] | Product Name: atrasentan INN or Proposed INN: atrasentan Other descriptive name: ATRASENTAN | Chinook Therapeutics U.S., Inc. | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 80 | Phase 2 | United States;Spain;Australia;United Kingdom;Korea, Republic of | ||
| 2 | EUCTR2020-004176-18-IT (EUCTR) | 08/06/2021 | 08/06/2021 | A Phase 2, Open-Label, Basket Study of Atrasentan in Patients with Proteinuric Glomerular Diseases (The AFFINITY Study) | A Phase 2, Open-Label, Basket Study of Atrasentan in Patients with Proteinuric Glomerular Diseases (The AFFINITY Study) - AFFINITY Study | Proteinuric glomerular diseases, including: Immunoglobulin A nephropathy (IgAN) (with UPCR 0.5 to <1.0 g/g)Focal segmental glomerulosclerosis (FSGS)Alport SyndromeDiabetes kidney disease (DKD) (as add-on to RAS and sodium glucose co-transporter 2 [SGLT2] inhibitors);Therapeutic area: Diseases [C] - Immune System Diseases [C20] | Product Name: atrasentan Product Code: [atrasentan] INN or Proposed INN: atrasentan Other descriptive name: ATRASENTAN | CHINOOK THERAPEUTICS, U.S., Inc | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 80 | Phase 2 | United States;Spain;Australia;United Kingdom;Italy;Korea, Republic of | ||
| 3 | NCT04573920 (ClinicalTrials.gov) | February 1, 2021 | 28/9/2020 | Atrasentan in Patients With Proteinuric Glomerular Diseases | A Phase 2, Open-Label, Basket Study of Atrasentan in Patients With Proteinuric Glomerular Diseases | IgA Nephropathy;Focal Segmental Glomerulosclerosis;Alport Syndrome;Diabetic Kidney Disease;Diabetic Nephropathy Type 2;Immunoglobulin A Nephropathy | Drug: Atrasentan | Chinook Therapeutics U.S., Inc. | NULL | Recruiting | 18 Years | N/A | All | 80 | Phase 2 | United States;Australia;Italy;Korea, Republic of;Spain;United Kingdom |